Overview
TSHA market data
Price History
TSHA price chart · 1M
- O
- 5.95
- H
- 6.09
- L
- 5.90
- C
- 6.01
- Vol
- 65,277.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.95
- Previous Close
- $6.01
- Day High
- $6.09
- Day Low
- $5.90
- 52 Week High
- $7.30
- 52 Week Low
- $5.17
- 7 Day Return
- -1.56%
- 30 Day Return
- +10.28%
- 90 Day Return
- +2.74%
- 1 Year Return
- -4.30%
- Daily Notional Volume
- $392.3K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -780.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.71 – $7.30 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.9B · P/B 6.10 · P/S 199.21.
Company News
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.Benzinga · Aug 12, 2026, 12:01 PM
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) EstimateBenzinga · Aug 11, 2026, 8:00 PM
Taysha Gene Therapies Announces Commercial Supply Agreement With Catalent For Rett Syndrome Gene Therapy TSHA-102 Ahead Of Potential FDA ApprovalBenzinga · Aug 3, 2026, 12:01 PM
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13Benzinga · Jul 21, 2026, 12:43 PM
Taysha Gene Therapies shares are trading lower after a Form 4 filing showed its President and Head of R&D sold 200,000 shares at an average price of $6.24 each.Benzinga · Jul 13, 2026, 2:24 PM
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price TargetBenzinga · Jul 2, 2026, 1:00 PM
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jun 30, 2026, 1:10 PM
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15Benzinga · Jun 30, 2026, 11:55 AM
8-K filing — Taysha Gene Therapies, Inc. (TSHA)SEC EDGAR · Jun 25, 2026, 8:26 PM
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market SessionBenzinga · Jun 25, 2026, 12:15 PM